Q2 FY2026 EarningsQ2 FY26 performance was headlined by a substantial revenue beat, totaling $72.5M vs. $63.5M expected, driven by a 73% QoQ surge in ZUSDURI® sales to $50.4M. Despite the top-line strength, GAAP Net Loss of $14.4M was slightly wider than the $13.9M consensus, as the company ramped up commercial investments. Operating expense guidance for FY26 was raised to $260M-$270M to support the ZUSDURI launch and pipeline acceleration (UGN-103/501), reflecting a strategic pivot toward growth over near-term profitability.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Urogen Pharma(URGN) the Revenue is 72.46 M (+199.2%), Beat estimate;the EBIT is 111 K (+100.3%), Beat estimate;the EPS is -0.28 (+73.33%), Meet estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.07B199.22%
0.06B162.40%
+0.01B36.82%
EBITExceed expectations
0.00B100.27%
-0.00B91.45%
+0.00B8.82%
EPS
-0.2873.33%
-0.2873.33%
0.00000.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf